[Back to Overwiew]  [IACM Homepage]

Boletín de la IACM del 13 de Marzo de 2020

IACM: 20º aniversario de la IACM

Hace 20 años un pequeño grupo de personas fundó la IACM, Asociación Internacional por el Cannabis como Medicamento, posteriormente rebautizada como Asociación Internacional por los Medicamentos Cannabinoides.

Al primer Congreso Internacional de la IACM sobre el uso de los Cannabinoides en Medicina, que se celebró en Berlín en 2001 en colaboración con el Hospital Charité y la Asociación Médica de Berlín, asistieron 80 participantes (científicos y médicos).

Hoy la IACM cuenta entre sus miembros a los investigadores y médicos más importantes involucrados en el uso médico del cannabis y los cannabinoides. Si bien en sus primeros congresos celebrados en universidades y en hoteles pequeños no asistieron más de 150 participantes y tuvieron un carácter familiar, el número ha aumentado espectacularmente en los últimos años, siendo en la actualidad de unos 450. Por primera vez, la duración del congreso aumentó de 2 a 3 días.

IACM: Congresos

La Junta Directiva de la IACM quiere que los Congresos de la IACM sean los más importantes sobre el uso del cannabis y los cannabinoides en medicina. Para conseguirlo, ha sido muy importante cambiar su frecuencia de celebración a anuales y trabajar con un organizador profesional de congresos, Congrex.

La IACM celebrará su 11º Congreso sobre el uso de los Cannabinoides en Medicina en la Ciudad de México del 7 al 9 de noviembre de 2020. Nuestro socio colaborador será la Asociación Mexicana de Medicina Cannabinoide. Esta asociación ya celebró un congreso, con alto nivel organizativo y de asistencia, en México en 2019. Será el primer congreso de la IACM fuera de EURopa.

El 12º Congreso de la IACM sobre uso de los Cannabinoides en Medicina se celebrará en Basilea, Suiza, del 14 al 16 de octubre de 2021. Nuestro socio colaborador será el Grupo de Trabajo Suizo sobre Cannabinoides en Medicina (SACM). El SACM ha organizado con éxito congresos científicos en Suiza durante varios años.

IACM: Seminarios web

Además, este año iniciaremos los seminarios web. Entre sus oradores estarán incluidos Ethan Russo, Donald Abrams, Manuel Guzmán, Kirsten Müller-Vahl, Franjo Grotenhermen, Raphael Mechoulam y Daniele Piomelli. Podremos oír a los principales expertos sobre temas importantes cómodamente desde casa.

IACM: Boletín

Durante 20 años, la IACM viene publicando de forma gratuita el Boletín IACM, actualmente en 6 idiomas. Durante este tiempo, se ha ido creado una base de datos integral de todos los hallazgos científicos relevantes, estudios clínicos y desarrollos políticos en varios países. La web también proporciona información adicional sobre el tema del cannabis y los cannabinoides en medicina.
www.cannabis-med.org/english/bulletin/iacm.php

IACM: Revistas

Ha habido intentos de establecer una revista de la IACM. En 2016 Cannabis and Cannabinoid Research (CCR), un periódico de acceso gratuito publicado por Mary Ann Liebert, Inc. y editado por Daniele Piomelli, se asoció con la IACM. En 2018 la IACM se adscribió con otro periódico, Medical Cannabis and Cannabinoids, publicado por Karger Publishers Basel. Su editor jefe es Rudolf Brenneisen.
En 2019 Cannabis and Cannabinoid Research se convirtió en el diario oficial de la IACM.
https://home.liebertpub.com/publications/cannabis-and-cannabinoid-research/633/overview

IACM: Junta Directiva

Kirsten Müller-Vahl, Alemania, primera presidenta
Manuel Guzmán, España, 2º presidente
Franjo Grotenhermen, Alemania
Roger Pertwee, Reino Unido
Ilya Reznik, Israel
Raquel Peyraube, Uruguay
Bonni Goldstein, EE. UU.
Debra Kimless, EE. UU.
Francisco Guimaraes, Brasil
Daniele Piomelli, EE. UU.

Anteriores presidentes de la IACM

Franjo Grotenhermen (2000-2003)
Raphael Mechoulam (2003-2005)
Roger Pertwee (2005-2007)
Kirsten Müller-Vahl (2007-2009)
Ethan Russo (2009-2011)
William Notcutt (2011-2013)
Daniela Parolaro (2013-2015)
Mark Ware (2015-2017)
Manuel Guzman (2017-2019)

IACM: Felicitaciones

Mahmoud A. ElSohly, Research Professor and Professor of Pharmaceutical and Drug Delivery, National Centre of Natural Products Research, School of Pharmacy, School of Mississippi, USA
(…) In the occasion of the 20th Anniversary of the International Association for Cannabinoid Medicines (IACM), I want to take the opportunity to congratulate you and all members of the IACM for 20 years of inspiring and world-class work aimed at advancing the field of cannabis and cannabinoids research. I joined the IACM in 2003 to explore this new organisation in the field that I chose to explore in my career. What a wise and rewarding choice it was. I have attended just about every meeting of the Association and in 2015, I had the honor of being presented the Special Award for Major Contributions to the Re-introduction of Cannabis as a medicine by Dr Grotenhermen himself. What a honour. I now always look forward to the next meeting and the opportunity to learn and to meet so many leaders in the field of cannabinoids research that I so much respect and admire. (…)

Roger Pertwee, Emeritus Professor, School of Medical Sciences Institute of Medical Sciences University of Aberdeen Foresterhill, Scotland, UK
I was delighted and felt enormously honoured to receive the Special Award of the International Association of Cannabinoid Medicines (IACM) at its 2013 meeting “for major contributions to the re-introduction of cannabis as a medicine”. (…) In addition, its meetings, its website and the IACM bulletin that is produced two or three times a month, provide a very effective and much needed means of educating physicians, patients and carers of patients about the actual and potential therapeutic uses of cannabis and cannabinoids. I know all this not least because I have attended every meeting of the IACM, including its first meeting in 2001, have served as the 2005 to 2007 IACM Chairman, and have been a member of the IACM board of directors for several years. Very importantly, the success of the IACM is and always has been due largely to its founder and executive director, Dr Franjo Grotenherman, who is a world-renowned clinical expert on cannabis and cannabinoid-based medicines, and who devotes an enormous amount of time and effective effort to the running of the IACM, including the organization of its meetings and the production of its bulletins. In conclusion, I wish the IACM a very happy 20th Birthday and as well as all the very best for its upcoming years.

Donald Abrams, Professor, Department of Medicine, Integrative Oncologist, UCSF Osher Center for Integrative Medicine, San Francisco, USA
Happy 20th IACM. Thanks for two decades of being at the forefront of cannabinoid education, providing clinicians and investigators with a convivial forum for networking, sharing and moving our maturing field forward. May we continue to grow and thrive in the upcoming decade, learning more about the therapeutic potential of the plant and its constituents to benefit patients worldwide.

Ricardo Navarrete-Varo, medical specialist in Family and Community Medicine, Andalusian Health Service (S.A.S.), Spain
Happy 20th birthday! It has been a real pleasure and pride to belong during all these years to one of the organizations that has contributed most to the reintroduction of cannabis and its derivatives in medicine, of such a high human and professional level. Special thanks to the person in charge, Dr. Franjo Grotenhermen, and a loving memory to those who were left behind, especially Dr. Ester Fride and Dr. Richard Musty.

Vincenzo Di Marzo, PhD,Research Director at the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Pozzuoli, Naples, Italy
"For 20 years the International Association for Cannabinoid Medicines, through its several conferences, publications and divulgation activities, has provided an indispensable forum for the critical discussion of the potential therapeutic applications of cannabis and cannabinoids, at the ideal cross-roads between basic and clinical research. Although I have not always been able to be active part of this organization, I immensely appreciate the role that IACM has played, and will continue to play, in the advancement of what is nowadays not only a field of research for me and many other colleagues, but also and foremost a real opportunity for the development of new medicines."

Ethan Russo, MD, Founder/CEO of CReDO Science cannabisresearch.org
The International Association for Cannabinoid Medicines marks its 20th anniversary in 2020. For two decades, IACM has been at the forefront of medical education on the clinical applications for cannabis, the most useful of medicinal plants. I am proud to have been a member of the organization, an awardee and former chairman of this organization that has done so much to clarify the role of cannabis in therapeutics.

Mario van der Stelt, Professor and Chair of Molecular Physiology, Leiden Institute of Chemistry Gorlaeus Laboratory, Leiden, The Netherlands
It is with great pleasure that I congratulate you and the board on the 20th anniversary of the Inernational Association for the Cannabinoid Medicines (IACM). Since its inception the IACM has advocated a science-based approach to study the medicinal effects of cannabinoids and the endocannabinoid system. Providing reliable, evidence-based information to patients and the general public about the potential therapeutic and adverse effects of (medicinal) cannabis was and will remain an important goal of the association. I wish you and the IACM success in this endeavor and many more successful meetings.

Mauro Maccarrone, Professor and Chair Biochemistry and Molecular Biology, Department of Medicine - Campus Bio-Medico University of Rome, Italy
In one week we will celebrate the 20th anniversary of the International Association for Cannabinoid Medicines (IACM), and I like to congratulate very much indeed with you on this major achievement. To all those involved (or simply interested) in cannabinoid and endocannabinoid research IACM has represented from the very beginning a reliable source of information, and a reference where to look for contacts and cross-fertilizations with colleagues from all over EURope, and beyond. Since my first participation in IACM conferences, I’ve admired your energy in pursuing initiatives such as publishing the IACM Bulletin (also translated in 7 different languages), organizing a yearly international meeting (always well-attended by professionals and lay people), awarding distinguished scientists for their contributions to basic and clinical science, as well as recognizing young researchers and outstanding leaders who advanced our knowledge in the field of cannabinoid medicines.
In 2007, I had myself the great pleasure and honour of receiving the IACM Award for Basic Research, with a laudatio by Ester Fride that I shall never forget. Few years later Ester sorrowly passed away, and the Award was named after her since then.
Franjo, let me take the liberty, also on behalf of our community, to thank you and the IACM Board for the impressive work that you have done for the field, and for establishing IACM as a compass to navigate the stormy sea of (endo)cannabinoid research.
Happy birthday, IACM, and good luck for the 20 years to come!

Hace un año - Hace dos años

Hace un año

Hace dos años

[Back to Overwiew]  [IACM Homepage]

up

Eventos en línea 2020

Toda la información sobre los eventos en línea de la IACM, incluidos los vídeos gratuitos de los seminarios web con subtítulos en español, puede encontrarse aquí.

Conferencia 2022

 La 12ª Conferencia de la IACM sobre Cannabinoides en Medicina se celebrará los días 20 y 21 de octubre de 2022 junto con la SSCM suiza en Basilea/Suiza.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.